In newborns affected by intraventricular hemorrhage (IVH), a complication that can arise in cases of fetal and neonatal alloimmune thrombocytopenia (FNAIT), commonly studied brain injury and inflammation markers may not predict treatment response or disease progression, according to a study published recently in World Neurosurgery.
This new study found no statistically significant link between levels of hemoglobin in cerebrospinal fluid, tumor necrosis factor-alpha or glial fibrillary acidic protein in the first weeks following diversion of cerebrospinal fluid, a standard treatment used to relieve pressure in the brain.
Eight preterm infants, all with grade 3 or 4 IVH, were included. All underwent placement of ventricular reservoirs to drain excess fluid. Although initial data hinted at a negative correlation between glial fibrillary acidic protein and hemoglobin levels, this relationship did not hold when more robust repeated measures analysis was applied.
“These results highlight the need for further research into biomarkers of brain injury after IVH,” explained this study’s authors. They continued, “It also highlights the importance of long-term longitudinal studies after IVH to understand better how biomarkers of brain injury change over time after IVH and potentially predict long term outcomes.”
Read more about FNAIT testing and diagnosis
Researchers also examined whether levels of biomarkers changed with time after treatment or correlated with one another. Across multiple methods, no strong or statistically significant associations were found.
Patients affected by FNAIT are already at risk for bleeding complications such as IVH. This study aimed to explore whether laboratory biomarkers in spinal fluid could help physicians assess injury or inflammation in the brain. The results suggest that these markers, at least early after diversion of cerebrospinal fluid, show too much variability and are not sufficiently consistent for clinical decision-making.
Even though this study was small, it highlighted the complexity of using laboratory values to monitor brain injury in fragile newborns. For families and caregivers, this means that decisions about care for babies with IVH, whether related to FNAIT or other causes, still depend heavily on imaging, symptoms, and clinical judgment rather than lab tests alone.
Every infant in this study eventually required placement of a permanent shunt, reflecting the seriousness of their brain injury. More research is needed to understand if and when these biomarkers might have value later in treatment or help predict longer-term outcomes.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
